These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2258142)

  • 1. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection.
    Lok AS; Lai CL; Leung EK
    Hepatology; 1990 Dec; 12(6):1266-70. PubMed ID: 2258142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.
    Barbera C; Bortolotti F; Crivellaro C; Coscia A; Zancan L; Cadrobbi P; Nebbia G; Pillan MN; Lepore L; Parrella T
    Hepatology; 1994 Aug; 20(2):287-90. PubMed ID: 8045488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
    Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
    Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection.
    Ozen H; Koçak N; Yüce A; Gürakan F
    Pediatr Infect Dis J; 1999 Aug; 18(8):694-7. PubMed ID: 10462338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
    Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.
    Hadziyannis S; Bramou T; Makris A; Moussoulis G; Zignego L; Papaioannou C
    J Hepatol; 1990; 11 Suppl 1():S133-6. PubMed ID: 2079571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
    Zavaglia C; Bottelli R; Bellati G; Asti L; Mondazzi L; Iamoni G; Zanetti A; Tanzi E; Fesce E; Gelosa F; Maggi G; Ideo G
    Ital J Gastroenterol; 1996; 28(6):324-31. PubMed ID: 8891847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing.
    Perrillo R; Mimms L; Schechtman K; Robbins D; Campbell C
    Hepatology; 1993 Dec; 18(6):1306-12. PubMed ID: 8244253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
    Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
    Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies during alpha-interferon therapy for chronic hepatitis B.
    Fattovich G; Betterle C; Brollo L; Pedini B; Giustina G; Realdi G; Alberti A; Ruol A
    J Med Virol; 1991 Jun; 34(2):132-5. PubMed ID: 1890413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B.
    Kanai K; Kako M; Aikawa T; Hino K; Tsubouchi H; Takehira Y; Iwabuchi S; Kawasaki T; Tsuda F; Okamoto H; Miyakawa Y; Mayumi M
    Am J Gastroenterol; 1996 Oct; 91(10):2150-6. PubMed ID: 8855739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
    J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B.
    Kako M; Kanai K; Aikawa T; Iwabuchi S; Takehira Y; Kawasaki T; Tsubouchi H; Hino K; Tsuda F; Okamoto H; Miyakawa Y; Mayumi M
    J Clin Gastroenterol; 1997 Sep; 25(2):440-5. PubMed ID: 9412946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection.
    Marinos G; Smith HM; Naoumov NV; Williams R
    Hepatology; 1994 Feb; 19(2):303-11. PubMed ID: 8294088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfa-2b therapy in children with chronic hepatitis B.
    Sokal EM; Wirth S; Goyens P; Depreterre A; Cornu C
    Gut; 1993; 34(2 Suppl):S87-90. PubMed ID: 8314496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole.
    Fattovich G; Giustina G; Brollo L; Guido M; Pontisso P; Noventa F; Alberti A
    Hepatology; 1992 Nov; 16(5):1115-9. PubMed ID: 1427652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
    Di Bisceglie AM; Fong TL; Fried MW; Swain MG; Baker B; Korenman J; Bergasa NV; Waggoner JG; Park Y; Hoofnagle JH
    Am J Gastroenterol; 1993 Nov; 88(11):1887-92. PubMed ID: 8237937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.